alomfilimab + atezolizumab

Alomfilimab (KY1044) + atezolizumab is a combination immunotherapy treatment being investigated for advanced cancers. Alomfilimab is a fully human IgG1 antibody that targets the Inducible T-cell Co-Stimulator (ICOS) with a dual mechanism of action: it depletes ICOS-high regulatory T cells (Tregs) and stimulates ICOS-low effector T cells (Teffs). Atezolizumab is an established PD-L1 inhibitor. The combination is being studied in a Phase 1/2 clinical trial (NCT03829501) for patients with advanced relapsed/refractory malignancies, with preliminary data showing objective responses in several cancer types including triple-negative breast cancer, head and neck squamous cell carcinoma, penile cancer, and pancreatic cancer.